DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Small Molecule Drugs cited in Almirall LLC v. Taro Pharmaceutical Industries Ltd.
|Date Filed||Document No.||Description||Snippet||Link To Document|
|2019-01-24||137||would induce infringement of U.S. Patent No. 9,517,219 (“the ’219 patent”) under the doctrine of equivalents…asserted claims are invalid. The ’219 patent is a method patent. The matter is set for trial on February…since the language of the asserted patent claims, and not the patent holder’s commercial product, to define… that during the prosecution of the ’219 patent, the patent examiner defined a POSA as having a level… a POSA for the ’219 patent. Taro proposes: A POSA for the ’219 patent would have had at least||External link to document|
|>Date Filed||>Document No.||>Description||>Snippet||>Link To Document|